News

Study Reveals Multiple Myeloma Treatment Disparities Between Caucasian, African-American Patients

Celgene Corporation recently presented a study comparing overall survival, treatment patterns, and healthcare costs between Caucasian (white-skinned) and African-American Medicare beneficiaries who were diagnosed with multiple myeloma, revealing there are discrepancies in treatment initiation between the two patient populations and discussing the impact of these inequalities on clinical outcomes. The study was presented at…

Revlimid Maintenance Following Stem Cell Transplant in Multiple Myeloma Patients Appears to Improve Overall Survival

Researchers at Buffalo, New York’s Roswell Park Cancer Institute (RPCI) have showed that maintenance lenalidomide (marketed as Revlimid) following autologous hematopoietic stem cell (HSC) transplant improves the overall survival of multiple myeloma patients. The findings from the study “Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell…

ASCO 2016: Updated Data of MOR202 for Multiple Myeloma Presented by MorphoSys

In a poster presentation at the 2016 ASCO Annual Meeting in Chicago, MorphoSys presented updated safety and efficacy data from an ongoing open-label, multicenter, Phase 1/2a clinical trial investigating MOR202 monotherapy in combination with lenalidomide (Len) and pomalidomide (Pom) plus dexamethasone (Dex) in 63 patients with relapsed/refractory multiple myeloma…

Iceni Planning a Phase 2 Study of Cilengitide in Multiple Myeloma Patients

Iceni Pharmaceuticals, formerly known as Big DNA Ltd., announced plans to soon begin testing its lead product Cilcane (cilengitide) as a first-in-class treatment for multiple myeloma (MM). The company, working with Merck Serono, was previously evaluating cilengitide in late-stage clinical trials as a potential treatment for glioblastoma, a brain cancer. Cilengitide is…